| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 225.3 | 54.3 |
| Profit before tax | -266.4 | -3.5 |
| Net income | -236.3 | -3.5 |
| EPS (diluted, $ a share) | $-2.64 | $-0.04 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +314.6% |
|---|---|
| Operating margin | -117.0% |
10-Q filed with the SEC, NASDAQ: LQDA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Liquidia Corp: key numbers
- Share price
- $56.37Close, Nov 16
- Market cap
- $5.08B
- Shares outstanding
- 90.11MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Liquidia Corp
All →Liquidia Financial Results
Liquidia Corporation reported Q3 2026 financial results, highlighted by $222.7 million in YUTREPIA net product sales, a 31% increase over the prior quarter. The company recorded a net loss of $236.3 million, which was primarily driven by a $389.7 million litigation settlement charge to resolve all outstanding disputes with United Therapeutics. Liquidia ended the quarter with $396.1 million in cash and cash equivalents.
- Term
- Q3 2026
“Five quarters after launch, YUTREPIA has rapidly established a preferred product profile because physicians value the control and flexibility it gives them over each patient’s therapy. That affinity and broad adoption have proven durable and our business continues to grow in parallel. With the litigation now fully resolved, and YUTREPIA’S commercial availability secure, we can fully focus on cementing the value of YUTREPIA through Phase 4 studies in PAH that will position it as the best-in-class inhaled therapy and first-in-choice prostacyclin.”
Dr. Roger Jeffs, Liquidia’s Chief Executive Officer
Liquidia CAO Dana Boyle Sells $68.3K of Stock
Dana Boyle, CAO, sold 1,581 shares of Liquidia Corp at $43.19 a share, worth $68.3K in total on Oct 26, 2026. Shares held after the trade: 164,028 (-1.0%).
- Value
- $68.3K
- Shares
- 1,581
- Price
- $43.19
- Role
- CAO
- Holding change
- -1.0%
- Trade date
- Oct 26, 2026
Liquidia Chief Business Officer Jason Adair Sells $29.7K of Stock
Jason Adair, Chief Business Officer, sold 688 shares of Liquidia Corp at $43.19 a share, worth $29.7K in total on Oct 26, 2026. Shares held after the trade: 177,269 (-0.4%).
- Value
- $29.7K
- Shares
- 688
- Price
- $43.19
- Role
- Chief Business Officer
- Holding change
- -0.4%
- Trade date
- Oct 26, 2026
Liquidia Court & Legal Update
Liquidia Corporation entered into a global settlement agreement with United Therapeutics to resolve all ongoing patent infringement, trade secret, and antitrust litigation. Liquidia will make aggregate payments of $320.4 million to UTC ($175M net initial payment plus $145.4M in 2027 installments) while agreeing to remove the PH-ILD indication from its YUTREPIA label to maintain the product's availability for PAH patients.
- Counterparty
- United Therapeutics Corporation
“Today’s agreement fully resolves years of litigation and provides certainty to PAH patients that they can continue to access YUTREPIA, whose differentiated attributes have enabled its rapid adoption by physicians and patients since launch.”
Dr. Roger Jeffs, CEO
Liquidia General Counsel Russell Schundler Sells $390K of Stock
Russell Schundler, General Counsel, sold 13,692 shares of Liquidia Corp at $28.48 a share, worth $390K in total on Oct 12, 2026. Shares held after the trade: 602,841 (-2.2%).
- Value
- $390K
- Shares
- 13,692
- Price
- $28.48
- Role
- General Counsel
- Holding change
- -2.2%
- Trade date
- Oct 12, 2026
Liquidia CMO Rajeev Saggar Sells $263K of Stock
Rajeev Saggar, CMO, sold 9,218 shares of Liquidia Corp at $28.48 a share, worth $263K in total on Oct 12, 2026. Shares held after the trade: 126,368 (-6.8%).
- Value
- $263K
- Shares
- 9,218
- Price
- $28.48
- Role
- CMO
- Holding change
- -6.8%
- Trade date
- Oct 12, 2026